News Briefs: Otezla for Pediatric Use Is Now Available
-
Sep 12, 2024
Otezla (apremilast) is available in the U.S. for the treatment of pediatric patients 6 to 17 years of age and weighing at least 20kg with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy, Amgen Inc. said Aug. 20. The FDA approved the agent for that use on April 25 while also registering an additional packaging facility to support new packaging configurations for the pediatric population. Read more
© 2025 MMIT
The Latest
Meet Our Reporters
Meet Our Reporters